-
公开(公告)号：US20210179687A1
公开(公告)日：2021-06-17
申请号：US16762273
申请日：2018-11-06
Inventor： Chengcheng ZHANG , Samuel JOHN , Heyu CHEN , Mi DENG , Xun GUI , Ningyan ZHANG , Zhiqiang AN
IPC: C07K14/705 , A61K45/06 , A61P35/02 , C12N5/0783
Abstract: The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment.
-
公开(公告)号：US20190031751A1
公开(公告)日：2019-01-31
申请号：US16075711
申请日：2017-02-06
Inventor： Ningyan ZHANG , Zhiqiang AN , Anil K. SOOD
IPC: C07K16/22 , A61P35/00 , A61K9/00 , C12N15/113
Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
-
公开(公告)号：US20230068663A1
公开(公告)日：2023-03-02
申请号：US17759800
申请日：2021-01-28
Inventor： Zhiqiang AN , Ningyan ZHANG , Zhiqiang KU , Chengcheng ZHANG , Xiaoye XU , Heyu CHEN , JingJing XIE , Maria Jose COSTA , An SONG , X. Charlene LIAO
IPC: C07K16/28 , A61K45/06 , A61K47/68 , A61P35/02 , A61K39/395 , G01N33/574
Abstract: Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.
-
公开(公告)号：US20210371518A1
公开(公告)日：2021-12-02
申请号：US17275838
申请日：2019-09-12
Inventor： Zhiqiang AN , Chengcheng ZHANG , Ningyan ZHANG , Xun GUI , Mi DENG , Tao HUANG , Qiang LIU , X. Charlene LIAO
IPC: C07K16/28 , A61P35/02 , A61K45/06 , A61K39/395 , A61K47/68 , A61K51/10 , G01N33/574 , A61K47/69
Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.
-
公开(公告)号：US20210130450A1
公开(公告)日：2021-05-06
申请号：US17096280
申请日：2020-11-12
Inventor： Ningyan ZHANG , Zhiqiang AN , Anil K. SOOD
IPC: C07K16/22 , C12N15/113 , G01N33/574 , A61P35/00 , A61K9/00
Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
-
Patent Agency Ranking
公开(公告)号：US20200079851A1
公开(公告)日：2020-03-12
申请号：US16678049
申请日：2019-11-08
Inventor： Chengcheng ZHANG , Mi DENG , Wei XIONG , Zhiqiang AN , Ningyan ZHANG , Xun GUI , Junke ZHENG
IPC: C07K16/28 , G01N33/574 , C07K16/30 , A61K45/06 , A61K39/395 , A61P35/02 , C12N15/113
Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
-
公开(公告)号：US20180066066A1
公开(公告)日：2018-03-08
申请号：US15643690
申请日：2017-07-07
Inventor： Ningyan ZHANG , Zhiqiang AN
IPC: C07K16/32 , G01N33/574 , A61F7/10 , A61N5/10
CPC classification number: C07K16/32 , A61F7/10 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57484 , G01N33/57492
Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
-
公开(公告)号：US20240383999A1
公开(公告)日：2024-11-21
申请号：US17995214
申请日：2021-04-01
Inventor： Ningyan ZHANG , Zhiqiang AN , Zhiqiang KU , Hui DENG , Lingegowda S MANGALA , Anil K. SOOD
Abstract: Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.
-
公开(公告)号：US20240376199A1
公开(公告)日：2024-11-14
申请号：US18691229
申请日：2022-09-13
Inventor： Zhiqiang AN , Ningyan ZHANG , Peng ZHAO
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments etc., that specifically bind a TREM2 protein or a TREM2 protein epitope, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20240101667A1
公开(公告)日：2024-03-28
申请号：US18255745
申请日：2021-12-02
Inventor： Chengcheng ZHANG , Guojin WU , Jaehyup KIM , Heyu CHEN , Mi DENG , Zhiqiang AN , Ningyan ZHANG , Ryan HUANG
IPC: C07K16/28 , A61P35/02 , G01N33/574 , G01N33/577
CPC classification number: C07K16/2803 , A61P35/02 , G01N33/574 , G01N33/577 , A61K2039/505 , C07K2317/24 , C07K2317/76 , C07K2317/92
Abstract: Provided herein are methods and compositions for the identification of modulators of LILRB3 activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor LILRB3 activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of LILRB3 activation to a subject.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.035 seconds)
